Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.53, p.119-127, 2006 |
||
Title: Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer | ||
Author: R., VYZULA ; I., KOCAKOVA ; R., R. DEMLOVA ; I., KISS ; L., DUSEK ; J., JARKOVSKY ; | ||
Abstract: The primary endpoint of this study was to evaluate the efficacy
(objective response rate; ORR) of combined chemotherapy
with raltitrexed plus oxaliplatin as second-line treatment in
patients with metastatic colorectal cancer (CRC). Secondary
endpoints were overall survival (OS), time to progression (TTP)
and toxicity (NCI-CTC criteria).
The target population were patients with metastatic colorectal
adenocarcinoma who progressed after first-line chemotherapy.
Treatment consisted of raltitrexed 3 mg/m2 as a 15-minute
intravenous (IV) infusion followed 45 minutes later by
oxaliplatin 130 mg/m2 IV as a 2-h infusion on Day 1, repeated
every 3 weeks until further disease progression (PD), unacceptable
toxicity or the decision of the patient.
Atotal of 51 patients, all withWHOperformance status 0–2 received
a median of 6 treatment cycles (range 1–11). After 3
cycles, 8 of the 47 evaluable patients (17%) had experienced an
ORR, 28 patients (59.6%) had experienced stable disease
(SD) and 11 patients (23.4%) had PD. After 6 cycles, 1 of the 29
evaluable patients (3.5%) had an ORR, 13 patients (44.8%)
had SD and 15 patients (51.7%) had PD. After a median follow-up of
48.9 weeks, median TTP was 18 weeks and median
overall survival was 54.4 weeks. Treatment was well tolerated;
grade 3 toxicities occurred in only 5/51 patients (9.8%). The
most common toxicities were paraesthesia (62.7%), diarrhoea
(23.5%), nausea (41.2%), vomiting (33.3%), hepatotoxicity
(25.5%), and hematological toxicity (41.2%).
In conclusion, the combination of oxaliplatin plus raltitrexed
appears to be effective and well tolerated as second-line
therapy in patients with disseminated CRC.
|
||
Keywords: colorectal cancer, palliative chemotherapy, raltitrexed, oxaliplatin | ||
Year: 2006, Volume: 53, Issue: | Page From: 119, Page To: 127 | |
|
download file |
|